Under endothelial Ephrin-B2 depletion, there were no significant differences in the neurological symptoms, metastatic loci, individual and total metastasis volume and tumor angiogenesis between either therapeutic group compared to placebo treated animals (Figure 5a–d). This evidence concerns the gene EFNB2 and neoplasm.